Study Description
The objective of this study is to evaluate the effect of erenumab on medication-specific
treatment satisfaction in patients newly started on erenumab over 12 weeks This is a longitudinal prospective descriptive primary data collection using a 20 min
online survey. Patients will be selected by investigators (general neurologists,
headache/migraine specialists) in primary care clinics and hospitals. After fulfilling
the inclusion criteria, the patient will be asked to sign an online informed consent. A 5
min screener will follow after which the patient will be directed through a link to the
full survey. The duration of data collection will be for 6 months since the start of
survey rolling in each site across centers in the Gulf Region.
Interventions
erenumab
Eligibility Criteria
Inclusion Criteria:
- EM& CM (with or without Medication Overuse Headache (MOH)) patients
- Newly Started on erenumab either 70 mg or 140 mg (first dose received within 1 month
prior study enrollment and baseline endpoints collection)
- Ability to receive 3 monthly doses of erenumab.
- Age more than 18 years
- Males and Females
- Allowing the patients to be stable on 1 adjunctive migraine preventive medication
(if present)
- Agreed to be included in the study and signed informed consent
Exclusion Criteria:
- Less than 18 years
- Age at onset of Migraine more than 50 years
- Any contraindications to the start of erenumab as per label
- Refusal to sign informed consent
- Inability to participate or restricted access to the online survey
- Enrolled in an interventional migraine-related study at the time of the study
enrollement
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.